Category: Press Releases

Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

Genprex today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.

Read More

Genprex Strengthens Senior Team and Continues to Advance Operations

Genprex announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately.

Read More

Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors

Genprex announced today the appointment of John N. Bonfiglio, PhD, to the company’s Board of Directors.

Read More

Genprex to Present at NobleConXV in Fort Lauderdale, Florida

Noble Capital Markets' Fifteenth Annual Investor / Equity Conference

Read More

Genprex to Present at Biotech Showcase™ 2019 in San Francisco

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2019-- Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019.

Read More

Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 12, 2018-- Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019.

Read More

Genprex to Present at the 11th Annual LD Micro Main Event

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 3, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More

Genprex Recognized as Finalist in Technology Innovation Category for Fierce Innovation Awards

AUSTIN, TX, November 29, 2017 – Genprex, Inc., a clinical stage gene therapy company, announced today that is has been selected as a finalist in this year’s Fierce Innovation Awards: Life Sciences Edition brought to you by the publisher of FierceBiotech and FiercePharma.

Read More

Genprex Provides Clinical and Corporate Update for Third Quarter 2018

AUSTIN, Texas--(BUSINESS WIRE)--Nov. 20, 2018-- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update

Read More

Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 30, 2018-- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN

Read More

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link